Objective To determine the characteristics of term infants with persistent pulmonary hypertension of the newborn (PPHN) associated with moderate or severe hypoxic ischemic encephalopathy (HIE).
M
oderate hypothermia (33.5°C) is neuroprotective in infants who suffer from perinatal hypoxic-ischemic encephalopathy (HIE). The American Academy of Pediatrics 1 and Neonatal Resuscitation Program 2 support whole-body or selective head cooling for neonates with moderate to severe HIE. Persistent pulmonary hypertension of the newborn was reported in 6%-25% neonates with HIE enrolled in the clinical trials of head and whole body cooling [3] [4] [5] and is higher than the incidence of PPHN in the general population (1.9 per 1000 live births). 6 The definition of PPHN in these trials was variable and based on clinical features, presence of hypoxemic respiratory failure, echocardiography, or use of inhaled nitric oxide (iNO).
There are several potential mechanisms causing hypoxemic respiratory failure and PPHN in asphyxiated newborn infants. 7 Fetal hypoxemia, meconium aspiration syndrome (MAS), sepsis, ventricular dysfunction, and acidosis can increase pulmonary vascular resistance (PVR) and result in PPHN. Among fatal cases of PPHN secondary to MAS, 10 of 11 infants had evidence of remodeling of intra-acinar pulmonary arteries at autopsy contributing to increased PVR. 8, 9 In the first Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Rockville, MarylandNeonatal Research Network trial (induced hypothermia [IH] ), moderate hypothermia to 33.5°C was not associated with an increase in the incidence of PPHN or the need for iNO and extracorporeal membrane oxygenation (ECMO) compared with the normothermia group (25% vs 22%). In the optimizing cooling (OC) strategies trial, the incidence of PPHN among infants cooled to 33.5°C was 20%. However, in the OC trial where neonates were randomly assigned to 4 combinations of duration and depth of cooling, whole body hypothermia to 32°C for duration of 72 or 120 hours was associated with an increased use of iNO and ECMO, compared with infants randomized to the 33.5°C cooling for either 72 or 120 hours. 10 Currently, moderate hypothermia with a core temperature of 33.5°C for 72 hours initiated within 6 hours of birth is recommended for newborns with moderate or severe HIE. 1, 2, 11 Our primary objective was to determine the clinical characteristics and comorbidities before delivery, intrapartum, and during the hospital course prior to discharge that were associated with PPHN in term neonates with moderate to severe HIE. We hypothesized that lung disease (eg, MAS, pulmonary hemorrhage), sepsis, and cardiac dysfunction would be more common in neonates with HIE who also had PPHN, and that infants with PPHN would have a lower PaO2 at baseline, higher rate of severe encephalopathy, and higher mortality. We also evaluated the use of iNO and ECMO in infants with PPHN and compared the mortality between infants with and without PPHN. We used prespecified data collected from 2 randomized controlled trials, IH and OC. Because prolonged (120 hours) and deeper cooling (32°C) are not standard of care, we excluded infants enrolled in these arms from the OC trial.
Methods
This study was a secondary analysis of data from the NICHD IH Trial (IH-NCT00005772, 2000 -2003 and the "usual care" arm (33°C for 72 hours) of the optimizing cooling strategies trial (OC-NCT01192776, 2010 . For both trials, infants were screened if they were of gestational age ≥36 weeks and were admitted to the neonatal intensive care unit at <6 hours of age, with an admitting diagnosis of acute perinatal asphyxia, neonatal depression, encephalopathy, and/or fetal acidemia. Infants were evaluated according to physiologic criteria and a neurologic examination. Eligibility criteria included pH of ≤7.0 or base deficit of ≥16 mmol/L in cord blood or during the first 1 hour after birth. If, during this interval, the pH was between 7.01 and 7.15, the base deficit was between 10 and 15.9 mmol/L, or an arterial blood gas value was not available, then additional criteria were required (an acute perinatal event and either a 10-minute Apgar score of ≤5 or assisted ventilation for ≥10 minutes from birth). Once these criteria were met, all infants underwent a standardized neurologic examination, performed by a certified physician. Encephalopathy was defined as ≥1 moderate or severe signs in at least 3 of the 6 categories. The number of moderate or severe signs determined the degree of encephalopathy; if signs were distributed equally, then the designation was based on the level of consciousness. Moderate or severe encephalopathy or seizures qualified infants for the trials.
The diagnosis of PPHN was based on clinical signs consistent with this diagnosis and echocardiographic evidence of pulmonary hypertension (ie, no structural heart disease; positive indication of elevated pulmonary arterial pressure; and/or flattened ventricular septum). 12 The centers were instructed to obtain and report blood gases at patient's actual temperature. The interpretation of echocardiograms, ventilator management, use of iNO, and ECMO was as per individual center practices. The distribution of patients in various arms of these trials is shown in Figure 1 . 
Statistical Analyses
Maternal characteristics (including intrapartum complications and mode of delivery), baseline neonatal characteristics, respiratory variables, mortality, length of stay, and associated organ dysfunction were analyzed for differences among babies with and without PPHN using c 2 or Fisher exact tests for categorical variables and t tests for continuous variables. Logistic and linear regression analyses were also conducted for mortality and length of stay to compare outcomes for babies with and without PPHN, while adjusting for severity of HIE. All reported P values are 2-sided and not adjusted for multiple comparisons; a P value of less than .05 was considered statistically significant. The statistical software used was SAS v 9.4 (SAS Institute, Cary, North Carolina).
Results
The IH trial enrolled 208 infants ≥36 weeks of gestation at birth with moderate to severe HIE. 13 In this trial, 102 infants were assigned to the whole-body hypothermia group (target esophageal temperature of 33.5°C for 72 hours) and 106 were assigned to the normothermia group (Figure 1) . The OC strategies trial randomized 364 infants to 4 arms with differing core target temperature and duration of therapeutic hypothermia: 33.5°C for 72 hours, 32°C for 72 hours, 33.5°C for 120 hours, and 32°C for 120 hours. Only the 95 subjects from 33.5°C for 72-hour arm of the OC trial were included in the present analysis. In total, 303 infants (208 from IH and 95 from OC trial) were evaluated.
Sixty-seven patients (22%) had a diagnosis of PPHN. Twentythree of 106 (21.7%) from the normothermia arm of the IH trial, 25 of 102 (24.5%) from hypothermia arm of IH trial, and 19 of 95 (20%) from the usual care arm of the OC trial had PPHN. Maternal characteristics, antepartum, intrapartum, and postnatal course during intervention and prior to discharge were compared between the PPHN group (n = 67) and the no-PPHN group (n = 236).
Maternal characteristics and intrapartum complications are shown in Table I . Maternal hypertension was less common in the PPHN group. All the other maternal measures were similar between PPHN and no-PPHN groups. Uterine rupture was less common in the PPHN group. Membranes were intact in more subjects in the PPHN group compared with no-PPHN group. Among mothers with rupture of membranes prior to delivery, the duration of rupture of membranes (either spontaneous or induced) was significantly shorter in PPHN group. Seventy percent of infants (213 of 303) were delivered by emergent cesarean delivery; there was no difference between PPHN and no-PPHN groups. Neonatal and delivery room resuscitation characteristics were similar in both groups and are shown in Table II . The majority of the 303 infants with moderate to severe HIE required resuscitation in the delivery room. Spontaneous respirations were delayed beyond 10 minutes in 181 of 286 infants (63.3%). The use of medications for resuscitation was more frequent in the PPHN group. Other resuscitative measures were performed at a similar frequency between the 2 groups ( Table II) .
The first postnatal gas showed significantly lower pH in the PPHN group. More infants with PPHN group were classified as having severe HIE based on the neurologic examination performed at <6 hours of postnatal age compared with the no-PPHN group (Table II) . The age at randomization was similar between the groups. Out of the 303 infants, 106 infants assigned to the control (normothermia group) arm of the IH trial were not treated with therapeutic hypothermia. The percentage of infants undergoing hypothermia was similar in PPHN and no-PPHN groups (Table III) . Sepsis with a positive blood culture was more common among infants with PPHN. The organisms isolated from blood culture are shown as footnotes in Table III .
Underlying pulmonary pathology was more common in infants with PPHN compared with the no-PPHN group (Table III) . MAS and pulmonary hemorrhage were more commonly observed in patients with PPHN. The use of high frequency ventilation was more common among infants with PPHN. Infants with PPHN were treated with higher FiO2 at baseline and throughout the period of intervention (Figure 2 , A; available at www.jpeds.com) to maintain PaO2 similar to the no-PPHN group (Figure 2, B) .
The cord pH was similar between the 2 groups. The pH on the first postnatal gas and at baseline was significantly lower ROM, rupture of membrane. Data shown as n (%), mean ± SD or median (IQR). *Significant at P < .05. †The 'n' in parentheses indicates that these data (exact duration of ROM) are available for some infants only.
in the PPHN group (Figure 3, A; available at www.jpeds.com). PCO2 on the cord gas was not reported and was significantly higher on the first postnatal gas in the PPHN group. There was no difference in PCO2 levels between the 2 groups at baseline and during the intervention period (Figure 3, B) .
As expected, use of iNO was more frequent among infants with PPHN ( Table III) . The specific indication for this therapy was not collected. Inhaled NO was used in 64% of infants with PPHN and 12% were placed on ECMO. Seven infants with moderate HIE in the no-PPHN group received iNO, and 6 of them were on FiO2 ≥0.8 and 4 died. These infants had hypoxemic respiratory failure but PPHN was not confirmed by echocardiogram. Four of these infants were in the control arm of the IH trial, and 3 were in the usual care arm of the OC trial.
Systemic hypotension, cardiomegaly, cardiac dysfunction, use of volume expanders, and inotropes were more common in the PPHN group (Table III) . The duration of inotrope therapy was more prolonged in the PPHN group. Oliguria and renal dysfunction were similar between groups (27 vs 22% in PPHN vs no-PPHN groups). There was no significant difference in neurologic status at the time of hospital discharge among survivors between the 2 groups (Table III) .
Among the 67 patients with PPHN, 8 (12%) received ECMO and 7 of these infants survived. Five patients died secondary to PPHN and/or MAS (including 1 death after ECMO) and 13 infants with PPHN had support withdrawn because of poor neurologic prognosis. Mortality was significantly higher in the PPHN group compared with no-PPHN group by unadjusted analysis (Table III) . When adjusted for severity of HIE, mortality was no longer significantly different in the PPHN group (adjusted OR 1.52, 0.76-3.02, P = .24), suggesting potential confounding between PPHN and baseline severity of HIE. Among infants with moderate HIE, mortality was significantly higher (OR 2.73, 1.01-7.39, P = .048) in the PPHN group (18%) compared with no-PPHN group (8%). Mortality was significantly higher with severe HIE (38%) and was not influenced by the presence of PPHN (38% mortality in both groups, OR 0.98, 0.40-2.41, P = .96). The causes of death are listed in Table III , and no significant differences were evident between the 2 groups. Among all infants, and among survivors to discharge, the length of stay was significantly prolonged in the PPHN group compared with no-PPHN group (Table III) after correcting for severity of HIE.
Discussion
We analyzed prespecified, prospectively collected data evaluating PPHN among infants with moderate to severe HIE. In our study, PPHN was observed in 22%of neonates with moderate to severe HIE. We found an association between comorbidities such as severe acidosis (first postnatal gas and at baseline), use of medications during delivery room resuscitation, underlying pulmonary pathology (MAS and pulmonary hemorrhage), hypercarbia on the first postnatal gas, high FiO2 at baseline, and presence of PPHN. Inhaled NO was used among approximately two-thirds and ECMO in 12% of infants with moderate/severe HIE and PPHN. Coexisting PPHN increased mortality among neonates with HIE.
We observed some differences in PPHN associated with HIE compared with that observed in general neonatal populations. [14] [15] [16] Black race, maternal diabetes, and maternal hypertension have been associated with increased PPHN in general neonatal populations, 15, 16 but this association was not evident in the current analysis. Interestingly, uterine rupture was less common (3% vs 13%) among infants with PPHN. We speculate that uterine rupture is an acute, symptomatic event leading to immediate recognition, rapid delivery, and prompt resuscitation and, hence, less likely to be associated with PPHN. However, we acknowledge that this difference could be due to small number of PPHN patients in our study.
The majority of infants with moderate or severe HIE required delivery room resuscitation. However, the increased use of medications during resuscitation of PPHN vs the no-PPHN infants with HIE suggests a common association of these factors with severe HIE. Fetal hypoxemia associated with severe HIE exacerbates pulmonary vasoconstriction. 17 In addition, Data shown as n (%) or mean ± SD. *Significant at P < .05. MRI, magnetic resonance imaging. Data shown as n (%) or mean ± SD. *Significant at P < .05. †Two infants in the PPHN group and 2 in the no-PPHN group had both early and late onset sepsis. ‡The organisms isolated from blood culture for 2 infants with PPHN and early onset sepsis: Streptococcus group B (n = 1) and Pseudomonas aeruginosa (n = 1). §The organisms isolated from blood culture for 3 infants without PPHN and early onset sepsis: Streptococcus group B (n = 2) and Staphylococcus coagulase negative (n = 1). ¶The organisms isolated from blood culture for 8 infants with PPHN and late onset sepsis: Streptococcus group B (n = 2), Serratia marcescens and coagulase-negative Staphylococcus (n = 1); Pseudomonas aeruginosa (n = 1); Hemophilus influenzae (n = 1); Staphylococcus epidermis or coagulase-negative (n = 3);. **The organisms isolated from blood culture for 6 infants without PPHN and late onset sepsis: Streptococcus group B (n = 2), Staphylococcus aureus (n = 1), Staphylococcus epidermis or other coagulase negative species (n = 2), Streptococcus viridans and Neisseria sp (n = 1). † †Data on home respiratory support (oxygen, ventilator) is missing in 8 infants. ‡ ‡One infant-cause of death was listed as MAS and asphyxial brain injury. § §One infant-pulmonary hemorrhage and disseminated intravascular coagulation; 2 infants listed as multiorgan failure and asphyxial brain injury.
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epinephrine is a pulmonary vasoconstrictor and may theoretically exacerbate PPHN. We also found that the incidence of MAS and pulmonary hemorrhage was significantly more common in the PPHN vs the no-PPHN group. Sarkar et al similarly demonstrated a high incidence of preexisting comorbidities such as parenchymal lung disease and perinatal stressors in patients with HIE developing PPHN. 18 Recently, Yum et al described a high incidence of MAS in patients with HIE and PPHN. 19 Randomized trials and epidemiologic studies have demonstrated the association between these respiratory pathologies and PPHN in general neonatal populations. 16, 20 Infants with HIE with associated respiratory pathology should be closely monitored for clinical and echocardiographic signs of PPHN.
As expected, increased acidosis on the first postnatal gas and at baseline was associated with PPHN. Both groups had a low cord gas pH of 6.9 ± 0.2. The no-PPHN group corrected the acidosis (7.1 ± 0.2 on the first postnatal gas and 7.33 ± 0.15 at baseline-mean time 4.5 hours after birth) while the PPHN infants remained acidotic during the first 6 postnatal hours (7.0 ± 0.2 on the first postnatal gas-mean time 1.3 hours after birth and 7.25 ± 0.21 at baseline). Blood pH and PCO2 levels (corrected for body temperature) normalized by 24 hours of intervention and were similar between both groups. Persistent acidosis, especially pH ≤7.25 is associated with hypoxic pulmonary vasoconstriction and PPHN. 20 The mortality associated with PPHN and moderate/severe HIE in our study (27%) is considerably higher than that reported in the general neonatal population. The California database reported a mortality of 7.6% among infants with PPHN, 16 and Konduri et al reported mortality of 8.5% in infants with moderate PPHN treated with iNO. 21 In the current study, 17 of the 50 infants (34%) treated with iNO died, including 7 with hypoxemic respiratory failure without echocardiography to confirm PPHN. Hypoxemic respiratory failure and PPHN associated with HIE and treated with iNO appears to have higher mortality compared with other causes of PPHN.
Adult animal studies have shown that hypothermia elevates PVR, 22 and in 1-to 3-day-old neonatal lambs, decreasing body temperature from 40°C to 30°C increased pulmonary arterial pressure from 29 to 40 mm Hg. 23 However, a metaanalysis of 4 major clinical trials involving 614 infants did not demonstrate an increased risk of PPHN with hypothermia in patients with HIE (typical RR 1.36; 95% CI 0.94-1.97), with no significant heterogeneity of treatment effect (I 2 = 0%). 12 We speculate that moderate hypothermia (33.5°C) induces mild pulmonary vasoconstriction in human infants with HIE. It is also possible that blood pressure, oxygenation, and acid-base balance are closely monitored in patients undergoing therapeutic hypothermia in these trials, preventing exacerbation of PPHN.
In addition to pulmonary vasoconstriction, HIE can be associated with cardiac dysfunction. 24, 25 Myocardial dysfunction can lead to secondary pulmonary venous hypertension. Hypothermia in neonatal lambs increased inferior vena caval pressure (central venous pressure) from 5 to 9 mm Hg and the left ventricular end-diastolic pressure from 8 to 25 mm Hg. 23 Cardiac dysfunction can be multifactorial-myocardial ischemic injury during asphyxia, increased right ventricular afterload due to PPHN, and reduced venous return secondary to high pressure from the ventilator. 7, 26 Systemic hypotension, cardiac dysfunction on echocardiogram, and cardiomegaly were more common in PPHN compared with the no-PPHN group, all of which increase the risk for right-to-left shunting in patients with PPHN.
There are several caveats to this study. The IH trial recruited patients from July 2000 to May 2003 13 and the OC trial between October 20, 2010 and November 27, 2013. 10 Changes in clinical management between 2003 and 2010 may have influenced our findings. The definition of baseline differed slightly between the 2 trials. For the IH trial, baseline was defined as time of randomization in the non-cooled group and time infant was placed on cooling blanket in the cooled group. For the OC trial, baseline was defined as the time of randomization; keeping in mind that the time of baseline and induction of cooling could be the same for some infants, and for other infants clinical cooling would have been initiated before randomization. The sample size of infants with PPHN was small, and we could not adjust for the year and center of enrollment. We did not record fluid balance and exact indications for volume and inotropes. Finally, the exact time of diagnosis of PPHN and indication and time at initiation of inhaled NO and ECMO were not recorded.
In summary, PPHN is commonly associated with HIE, particularly when lung disease (such as MAS and pulmonary hemorrhage), postnatal acidosis, culture-positive sepsis, systemic hypotension, and cardiac dysfunction are present. The prevalence of PPHN was not different between those infants receiving therapeutic hypothermia at 33.5°C in the IH (25%) and OC trials (25%) compared with normothermia in the IH trial (22%). The mortality for PPHN increases when associated with HIE. We recommend development of evidence-based protocols for the management of PPHN during therapeutic hypothermia at 33.5°C for infants with moderate to severe HIE. ■ THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 196 51.e3
